OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study ResultsStephen V. Liu, Martin Reck, Rafał Dziadziuszko et al.|Journal of Thoracic Oncology|2023Cited by 36
A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.Jianjun Zhang, Shun Lu, Joaquim Bosch‐Barrera et al.|Journal of Clinical Oncology|2025Cited by 2